Literature DB >> 130137

Cyclophosphamide protection in NZB/NZW disease. Mechanisms and therapeutic regimens.

A D Morris, J Esterly, G Chase, G C Sharp.   

Abstract

Regular administration of cyclophosphamide to NZB/NZW female mice effectively protects against the nephritis that is thought to be a model for human SLE nephritis. Reductions in serologic, histologic, and immunogluorescent parameters of the disease are correlated. Intermittent as well as continuous administration of the drug is effective without the development of leukopenia. Possible mechanisms of drug action and a modified approach to therapy of immune complex disease are discussed.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 130137     DOI: 10.1002/art.1780190108

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  13 in total

1.  Successful treatment of autoimmunity in (NZB X NZW)F1 mice with cyclosporin and (Nva2)-cyclosporin: II. Reduction of glomerulonephritis.

Authors:  H C Gunn; B Ryffel
Journal:  Clin Exp Immunol       Date:  1986-05       Impact factor: 4.330

2.  Levamisole maintains cyclophsophamide-induced remission in murine lupus erythematosus.

Authors:  J Zulman; J Michalski; C McCombs; J Greenspan; N Talal
Journal:  Clin Exp Immunol       Date:  1978-02       Impact factor: 4.330

3.  Effect of cyclophosphamide on glomerular permeability and localization of immunoreactants in NZB/NZW mice.

Authors:  O I Czechner; T Cavallo
Journal:  Clin Exp Immunol       Date:  1982-04       Impact factor: 4.330

4.  Effects of dazmegrel, piroxicam and cyclophosphamide on the NZB/W model of SLE.

Authors:  R L Archer; A C Cunningham; P F Moore; J A Potter; M L Bliven; I G Otterness
Journal:  Agents Actions       Date:  1989-06

5.  Effect of pulse dose cyclophosphamide on the anamnestic immune response in NZB/W mice.

Authors:  L Levy; D Chia; E V Barnett
Journal:  Agents Actions       Date:  1978-12

6.  Stimulated autoantibody response and increased longevity in NZB/NZW mice treated with cyclophosphamide and tilorone.

Authors:  S E Walker; M R Anver
Journal:  Clin Exp Immunol       Date:  1978-09       Impact factor: 4.330

7.  Murine lupus nephritis: effects of cyclophosphamide on circulating and tissue bound immunoreactants.

Authors:  T Cavallo; K Graves; N A Granholm
Journal:  Clin Exp Immunol       Date:  1984-01       Impact factor: 4.330

8.  Long term administration of cyclophosphamide in MRL/1 mice. I. The effects on the development of immunological abnormalities and lupus nephritis.

Authors:  M Shiraki; M Fujiwara; S Tomura
Journal:  Clin Exp Immunol       Date:  1984-02       Impact factor: 4.330

Review 9.  Placebo and the new physiology of the doctor-patient relationship.

Authors:  Fabrizio Benedetti
Journal:  Physiol Rev       Date:  2013-07       Impact factor: 37.312

10.  Murine mercury-induced immune-complex disease: effect of cyclophosphamide treatment and importance of T-cells.

Authors:  P Hultman; S Eneström
Journal:  Br J Exp Pathol       Date:  1989-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.